PBYI earnings analysis
What we found in PBYI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Puma Biotechnology reported Q1 2026 results with revenue of $44.8 million, exceeding estimates of $41.4 million, while EPS loss of -$0.04 surpassed expectations of -$0.14. Although total revenue decreased year-over-year from $46.0 million in Q1 2025, management raised full-year revenue guidance to $222-$229 million from $214-$221 million, driven by strong demand for NERLYNX.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beat Expectations
- Actual revenue was $44.8 million, outpacing estimates of $41.4 million.
- EPS Surprise
- Reported EPS loss of -$0.04 compared to estimates of -$0.14.
- Improved Cash Flow from Operations
- Operating cash flow was $15.4 million, significantly up from $3.6 million in Q1 2025.
- Strong Cost Control
- Operating expenses managed with SG&A increasing only by 4.7% to $18.4 million.
- Increase in Cash Reserves
- Cash and cash equivalents rose to $36.2 million from $29.6 million at year-end.
- Raised FY 2026 Revenue Guidance
- Management updated guidance to $222-$229 million from $214-$221 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased R&D Expenses
- R&D expenses rose to $19.8 million, a 42.8% increase from $13.9 million in Q1 2025.
- Decreased Total Revenue YoY
- Total revenue decreased from $46 million in Q1 2025 to $44.8 million.
- Ongoing Clinical Development Risks
- Continued reliance on alisertib's development success poses significant operational risks.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.04
What they said about what is next.
Management raised FY 2026 revenue guidance to $222-$229 million based on product demand.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Puma reported a Q4 2025 beat with revenue of $75.5M and EPS of $0.29, supporting a trailing twelve-month revenue roughly flat vs. 2024 (~$227M in 2025 vs. ~$231M in 2024). The business remains single-product (NERLYNX)…
- 10-Q · November 6, 2025
- Puma reported Q3 2025 total revenue of $54,475,000 and GAAP net income of $8,844,000 (diluted EPS $0.17). Revenue was up modestly versus the prior quarter but materially lower year-over-year due to a sharp drop in…
- 10-Q · May 8, 2025
- Puma reported Q1 2025 revenue of $46,007,000 (up $2,241,000 or 5.1% vs Q1 2024) and GAAP net income of $2,974,000 (EPS $0.06), a turnaround from a net loss of $(4,815,000) (EPS $(0.10)) in Q1 2024. Gross margin remained…
- 10-Q · November 7, 2024
- Puma reported a strong Q3: total revenue of $80.542M (up from $56.116M YoY) and net income of $20.317M (diluted EPS $0.41 vs $0.12 YoY). Operating profit expanded to $22.079M (27.4% margin) despite a meaningful…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PBYI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever